ARCH Venture Partners
Portfolio in United States: 3 funded startups tracked by Uback, 3 of them in a ranking.
Portfolio on Uback
Sorted by Uback rank, then Radar by last round| Company | Uback | Sector | Round backed | Valuation (AI) |
|---|---|---|---|---|
| Xaira Therapeutics | #3 AI drug discovery | Healthtech › Biotech › AI drug discovery | Launch financing · USD 1B+ committed · Apr 2024 | Unicorn |
| ArsenalBio | #4 Gene & cell therapies | Healthtech › Biotech › Gene & cell therapies | Series C · USD 325M · Sep 2024 | Unicorn |
| Create Medicines | #9 Gene & cell therapies | Healthtech › Biotech › Gene & cell therapies | Series B · USD 122M · May 2026 | Hundreds of M$ |
Only startups that meet Uback’s eligibility rules are shown. Amounts are round sizes, not the fund’s share. Rounds as reported by public sources.
By sector
Deals tracked per year
Co-investors
Foresite Labs · F-Prime · NEA · Sequoia Capital · Lux · Lightspeed · Regeneron · NVIDIA · T. Rowe Price · Bristol Myers Squibb · SoftBank Vision Fund · Newpath Partners · Hatteras Venture Partners
Investors that joined the same rounds, as reported by public sources.
Sources. arsenalbio.com, biopharmadive.com, biospace.com, drugdiscoverytrends.com, fiercebiotech.com, forgeglobal.com, as cited on each company’s profile.
Last updated: Sep 2026Report a missing dealReport an error
Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction.